Editorial Perspectives On Patient Recruitment
-
One Year In, DTRA Meets Goals & Looks To The Future
12/1/2021
In November 2021, the Decentralized Trial & Research Alliance (DTRA) held its annual meeting in Boston. The DTRA was formed in 2020 with more than 70 founding members from pharma companies and their technology and service partners. I took this opportunity to speak with Craig Lipset, DTRA’s co-chair, about the progress the organization has made and its vision for the future.
-
A Lesson Learned From Big Pharma: Don't Be Afraid To Go Global
11/19/2021
The rheumatic diseases Kezar Life Sciences is attempting to treat have racial disparities across the world that create different outcomes and incidence rates of autoimmune disorders. Those considerations must come into play when thinking about trial design. The company has learned you should not be afraid to go global as early as possible.
-
Hybrid Trials Are Impacting Clinical Research, But Do Patients Want Them?
11/11/2021
Clinical trials continue to evolve and have become increasingly complex. Studies now have more procedures, visits, and time spent at clinics during those visits. The Center for Information and Study on Clinical Research Participation (CISCRP) is celebrating its eighth year of focusing on the patient experience in clinical trials via its Perceptions and Insights study.
-
4 Factors Preventing Diversity In Trials – And How To Overcome Them
11/9/2021
A study conducted by advocacy group For The Breast of Us along with Sommer Consulting sought to determine the factors keeping women of color from participating in breast cancer clinical trials. Founded in 2019, For The Breast of Us is the first online community dedicated to women of color affected by breast cancer.
-
Decentralized Trials Can Overcome The Challenges Of Rare Disease Patients
10/5/2021
There are 400 million people worldwide who are impacted by more than 7,000 identifiable rare diseases. While individual rare diseases are uncommon, approximately 5% of the world’s population suffers from one. A new report from technology provider THREAD details how many of the clinical challenges posed by rare disease trials can be alleviated by decentralized trials.
-
Seagen Leverages Partnerships to Understand Patient Perspectives
9/30/2021
Patient recruitment, retention, and diversity in clinical trials has been an ongoing challenge. While there is an industry-wide effort underway to try and address these issues, they will not be truly impacted until researchers are able to create a better patient experience, do a better job of reaching patients from diverse communities, building true relationships, and working to co-create solutions as equal partners.
-
Liver Disease Requires A Patient-Centric Approach To Trials
9/1/2021
89bio is focused on two large markets which CEO Rohan Palekar believes are underserved. The first is fatty liver disease, which in its late stages is called non-alcoholic steatohepatitis (NASH). The second is severe hypertriglyceridemia, or high levels of fat in the blood. Creating trials for these diseases required a patient-centric approach.
-
How An External Control Arm Changed Phase 3 Trials For Brain Cancer
8/19/2021
Glioblastoma multiforme (GBM) is an aggressive and fatal form of brain cancer that can form in the brain or spinal cord. Unfortunately, drug development for patients with the disease has not seen much progress in decades. Dr. Fahar Merchant, president and CEO of Medicenna Therapeutics, a clinical stage immunotherapy company, is hoping to change that.
-
The Four Essential Pillars of Successful Patient Centric Trials
8/12/2021
Praxis Precision Medicines is a drug development company using genetic insights to focus on treatments for patients with CNS disorders. Praxis has patient centricity infused throughout the organization and believes taking care of patients and producing successful trials comes down to four essential factors: staff, sites, CROs, and patient insights.
-
How One Biotech Is Taking An Innovative Approach To Alzheimer's Disease
7/15/2021
Drug development in the Alzheimer’s space is difficult and has been plagued by successive failures over the last 18 years. One company working in that space felt it was time to take a new and innovative approach to find a treatment for patients.